摘要
小分子在细胞中选择性降解致病菌的研究对各种疾病包括癌症的治疗药物的发展是一种新的方法。我们和其他人已经开发了一系列的小分子化合物的混合蛋白敲除技术,称为SNIPERs(特异性和非遗传性的IAP依赖蛋白消除);和肽的嵌合分子,称为protacs(蛋白靶向嵌合分子),从而导致目标蛋白通过泛素-蛋白酶体途径选择性降解。这些化合物包括两种通过连接器链接的不同配体;一个是一种泛素连接酶配体,另一个是预计这些细胞中蛋白质交联的靶蛋白配体。从理论上讲,任何胞浆蛋白都可以通过这种技术完成降解的目标。到目前为止,几个针对具体诱导的致癌蛋白的泛素化和蛋白酶体降解各种致癌蛋白的SNIPERs和protacs已被开发,导致细胞死亡,生长停滞,或癌细胞迁移的影响。因此,这种蛋白敲除技术在癌症治疗方面有很大的潜力。
关键词: IAP,PROTAC(蛋白靶向嵌合分子),蛋白酶体,蛋白敲除,SNIPER(特异性和非遗传性的IAP依赖蛋白消除),泛素连接酶。
Current Cancer Drug Targets
Title:Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
Volume: 16 Issue: 2
Author(s): Nobumichi Ohoka, Norihito Shibata, Takayuki Hattori and Mikihiko Naito
Affiliation:
关键词: IAP,PROTAC(蛋白靶向嵌合分子),蛋白酶体,蛋白敲除,SNIPER(特异性和非遗传性的IAP依赖蛋白消除),泛素连接酶。
摘要: Selective degradation of pathogenic proteins by small molecules in cells is a novel approach for development of therapeutic agents against various diseases, including cancer. We and others have developed a protein knockdown technology with a series of hybrid small compounds, called SNIPERs (Specific and Nongenetic IAP-dependent Protein ERasers); and peptidic chimeric molecules, called PROTACs (proteolysis-targeting chimeric molecules), which induce selective degradation of target proteins via the ubiquitin-proteasome pathway. These compounds include two different ligands connected by a linker; one is a ligand for a ubiquitin ligase and the other is a ligand for the target protein, which are expected to crosslink these proteins in cells. Theoretically, any cytosolic protein can be targeted for degradation by this technology. To date, several SNIPERs and PROTACs against various oncogenic proteins have been developed, which specifically induce polyubiquitylation and proteasomal degradation of the oncogenic proteins, resulting in cell death, growth arrest, or impaired migration of cancer cells. Thus, this protein knockdown technology has a great potential for cancer therapy.
Export Options
About this article
Cite this article as:
Nobumichi Ohoka, Norihito Shibata, Takayuki Hattori and Mikihiko Naito , Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy, Current Cancer Drug Targets 2016; 16 (2) . https://dx.doi.org/10.2174/1568009616666151112122502
DOI https://dx.doi.org/10.2174/1568009616666151112122502 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets Alternative Splicing, DNA Damage and Modulating Drugs in Radiation Therapy for Cancer
Anti-Cancer Agents in Medicinal Chemistry Chemistry and Biology of the Cruciferous Phytoalexins Brassinin and Cyclobrassinin
The Natural Products Journal DLEU1: A Functional Long Noncoding RNA in Tumorigenesis
Current Pharmaceutical Design Pharmacological Approaches to Chronic Spinal Cord Injury
Current Pharmaceutical Design Dibenzoylmethane Activates Nrf2-Dependent Detoxification Pathway and Inhibits Benzo(a)pyrene Induced DNA Adducts in Lungs
Medicinal Chemistry Characterization and Inhibition of the Recently Discovered Carbonic Anhydrase Isoforms CA XIII, XIV and XV
Current Topics in Medicinal Chemistry Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs
Current Drug Metabolism Editorial [Hot Topic: Advanced Imagings of Wallerian Degeneration, Pancreatobiliary System, Uterine Cervical Cancer, Periventricular Leukomalacia, Living Cells as well as MR Contrast Agent and QC of SPECT/CT]
Current Medical Imaging Breast Cancer Diagnosis Using Data Mining Methods, Cumulative Histogram Features, and Gary Level Co-occurrence Matrix
Current Medical Imaging Editorial
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Biomarkers of Protein Oxidation in Human Disease
Current Molecular Medicine Advances of Inorganic Materials in the Detection and Therapeutic Uses against Coronaviruses
Current Medicinal Chemistry Cervical Cancer During Pregnancy – An Approach to Diagnosis and Management
Current Women`s Health Reviews DNA Vaccination in Oncology: Current Status, Opportunities and Perspectives
Current Clinical Pharmacology microRNAs: Innovative Targets for Cerebral Ischemia and Stroke
Current Drug Targets Exploiting APC Function as a Novel Cancer Therapy
Current Drug Targets Solubility Enhancement and Delivery Systems of Curcumin a Herbal Medicine: A Review
Current Drug Delivery Targeted Taxane Delivery Systems: Recent Advances
Drug Delivery Letters Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways
Current Neuropharmacology